CNSP — CNS Pharmaceuticals Cashflow Statement
0.000.00%
- $3.33m
- -$2.81m
Annual cashflow statement for CNS Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -9.46 | -14 | -15.3 | -18.9 | -14.9 |
Depreciation | |||||
Non-Cash Items | 1.29 | 1.72 | 1.54 | 1.01 | 1.44 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 0.834 | -1.24 | 3.16 | 3.7 | -3.69 |
Change in Prepaid Expenses | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Payable / Accrued Expenses | |||||
Cash from Operating Activities | -7.32 | -13.5 | -10.6 | -14.1 | -17.1 |
Capital Expenditures | -0.018 | -0.006 | -0.004 | -0.004 | -0.004 |
Purchase of Fixed Assets | |||||
Cash from Investing Activities | -0.018 | -0.006 | -0.004 | -0.004 | -0.004 |
Financing Cash Flow Items | -0.045 | 0 | — | — | -0.067 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 14.1 | 4.51 | 15.6 | 4.64 | 23 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 6.8 | -9.03 | 5.05 | -9.51 | 5.91 |